Catastrophic Antiphospholipid Syndrome (CAPS) Crisis Management
For acute CAPS management, immediately initiate triple therapy: full-dose anticoagulation (intravenous heparin), high-dose glucocorticoids (including IV methylprednisolone pulses), and either therapeutic plasmapheresis or intravenous immunoglobulin (IVIG 1 g/kg body weight). 1, 2, 3
Immediate Acute Management Algorithm
Step 1: Anticoagulation (Start Immediately)
- Intravenous unfractionated heparin is the preferred agent for acute CAPS
- Do NOT use direct oral anticoagulants (DOACs) in CAPS, especially with triple-positive antibodies or arterial thrombosis 2
- Transition to warfarin once stabilized 3
Step 2: Immunosuppression (Concurrent with Anticoagulation)
- High-dose glucocorticoids: IV methylprednisolone pulses (typically 500-1000 mg daily for 3 days) 3, 4
- Continue with oral prednisone taper after pulse therapy
- If associated with SLE flare, add cyclophosphamide 3
Step 3: Antibody/Cytokine Removal (Choose One or Both)
Therapeutic plasmapheresis (preferred first-line) 2, 3, 5
- Removes pathogenic autoantibodies and inflammatory cytokines
- Typically 5-7 exchanges over 10-14 days
OR/AND
Intravenous immunoglobulin (IVIG): 1 g/kg body weight 3, 5, 4
- Can be used alone or combined with plasmapheresis
- Particularly useful when plasmapheresis unavailable
Step 4: Address Precipitating Factors
- Aggressive antibiotic therapy if infection suspected (infection is a major trigger) 6, 3
- Surgical debridement/amputation of necrotic tissue if present 3
- High vigilance in post-operative or post-procedural settings 3
Critical Clinical Considerations
Mortality Context
CAPS carries 33-50% mortality in children 6 and approximately 50% overall mortality 5. This is a true medical emergency requiring ICU-level care.
Multi-Organ Involvement
CAPS is defined by acute failure of at least three organs/tissues/systems due to small vessel thrombosis 5. Look specifically for:
- Renal dysfunction (most common)
- Pulmonary involvement (ARDS, pulmonary embolism)
- Cardiac (microvascular coronary thrombosis, valve disease)
- Neurological (stroke, encephalopathy)
- Cutaneous (digital gangrene, livedo reticularis)
- Hematological (thrombocytopenia)
Emerging Therapy
Complement inhibition (eculizumab) shows promise in limited studies and should be considered in refractory cases, as complement activation is central to CAPS pathogenesis 6. This represents an important adjunctive option when standard triple therapy fails.
Common Pitfalls to Avoid
- Do NOT delay treatment waiting for antibody confirmation—clinical suspicion is sufficient to start therapy 3
- Do NOT use DOACs in acute CAPS or triple-positive patients 2
- Do NOT overlook infection as both trigger and complication—maintain high index of suspicion 6, 3
- Do NOT use antiplatelet agents alone—full anticoagulation is mandatory 2
- Do NOT stop anticoagulation abruptly in known APS patients, as this can precipitate CAPS 7
Long-Term Considerations After Acute Crisis
Once stabilized, patients require:
- Lifelong anticoagulation with warfarin (target INR 2-3, or 3-4 for arterial events)
- Consider adding low-dose aspirin for arterial thrombosis 2
- Rituximab may be considered for refractory cases to suppress antibody formation 6, 4
- Close monitoring for recurrent thrombosis
The multidisciplinary team should include rheumatology, hematology, critical care, and nephrology given the multi-system nature of this catastrophic condition 1.